Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action
The DOI matches its Crossref record; 121 of the 123 references it cites were found in a registry or an index.
Abstract
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently become a major concern for a broad spectrum of health care providers. Endocrinologists and those caring for patients with type 2 diabetes mellitus (T2DM) are at center stage, as T2DM appears to worsen the course of NAFLD and the liver disease makes diabetes management more challenging. However, the nature of this relationship remains incompletely understood. Although the increasing prevalence of NAFLD is frequently attributed to the epidemic of obesity and is often oversimplified as the "hepatic manifestation of the metabolic syndrome," it is a much more complex disease process that may also be observed in nonobese individuals and in patients without clinical manifestations of the metabolic syndrome. It carries both metabolic and liver-specific complications that make its approach unique among medical conditions. Diabetes appears to promote the development of nonalcoholic steatohepatitis (NASH), the more severe form of the disease, and increases the risk of cirrhosis and hepatocellular carcinoma. Patients and physicians face many uncertainties, including fragmented information on the natural history of the disease, challenges in the diagnosis of NASH, and few pharmacological agents with proven efficacy. However, recent advances in diagnosis and treatment, combined with the risk of serious consequences from inaction, call for health care providers to be more proactive in the managem…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NAFLD, and in particular NASH, is also associated with an increased risk of cardiovascular complications; therefore, people with NAFLD should have their cardiovascular risk factors assessed and managed to minimize this risk (303).”
In the citing paper
“Rat studies have shown that removal of visceral adipose tissue increases insulin sensitivity while delaying T2D (75), and prevents metabolic syndrome and NAFLD (76).”
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Williams, C. D., Stengel, J., Asike, M. I., Torres, D. M., Shaw, J., Contreras, M., Landt, C. L., & Harrison, S. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.09.038 · Cited by 2,148
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 4×
“However, cross-comparisons between studies should be avoided because of differences in the populations studied and other factors, such as differences in the proportion of patients with T2DM (60,79).”
BackgroundResultInfluentialSelf-citationWong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,775
Self-citationLoomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Hernaez, R., Lazo, M., Bonekamp, S., Kamel, I., Brancati, F. L., Guallar, E., & Clark, J. M. (2011) · Hepatology · doi:10.1002/hep.24452 · Cited by 1,585
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
Updated definitions of healthy ranges for serum alanine aminotransferase levels
Prati, D., Taioli, E., Zanella, A., Torre, E. D., Butelli, S., Del Vecchio, E., Vianello, L., Zanuso, F., Mozzi, F., Milani, S., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00006 · Cited by 1,445 · cited 1×
“, 30 IU/L for males and 19 IU/L for females) in order to improve the sensitivity of the method (34).”
MethodRandomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Self-citationAdams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Cusi, K. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.003 · Cited by 911
Self-citationHarrison, S. A., Oliver, D., Arnold, H. L., Gogia, S., & Neuschwander-Tetri, B. A. (2008) · Gut · doi:10.1136/gut.2007.146019 · Cited by 869
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Imajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
Lazo, M., Hernaez, R., Eberhardt, M. S., Bonekamp, S., Kamel, I., Guallar, E., Koteish, A., Brancati, F. L., & Clark, J. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws448 · Cited by 797
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766 · cited 1×
“Pioglitazone therapy also reduced the progression from prediabetes to T2DM by ;50% (82) to;70% (92).”
BackgroundBariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Musso, G., Gambino, R., Tabibian, J. H., Ekstedt, M., Kechagias, S., Hamaguchi, M., Hultcrantz, R., Hagström, H., Yoon, S. K., Charatcharoenwitthaya, P., et al. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001680 · Cited by 720
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2016) · Diabetologia · doi:10.1007/s00125-016-3902-y · Cited by 683
Mazzone, T., Meyer, P. M., Feinstein, S. B., Davidson, M. H., Kondos, G. T., D’Agostino, R. B., Perez, A., Provost, J.-C., & Haffner, S. M. (2006) · JAMA · doi:10.1001/jama.296.21.joc60158 · Cited by 674
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease
Ong, J. P., Pitts, A., & Younossi, Z. M. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.06.018 · Cited by 638
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Targher, G., Bertolini, L., Rodella, S., Tessari, R., Zenari, L., Lippi, G., & Arcaro, G. (2007) · Diabetes Care · doi:10.2337/dc07-0349 · Cited by 579
Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · cited 1×
“and have the advantage of being quantifiable, providing a tool to assess changes over time (40,44,45).”
MethodNon-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
Pais, R., Charlotte, F., Fedchuk, L., Bedossa, P., Lebray, P., Poynard, T., & Ratziu, V. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.027 · Cited by 522
Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Self-citationCaldwell, S. H., & Crespo, D. M. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.02.013 · Cited by 501
Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., & the LIDO Study Group (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12963 · Cited by 500
Ratziu, V., Massard, J., Charlotte, F., Messous, D., Imbert-Bismut, F., Bonyhay, L., Tahiri, M., Munteanu, M., Thabut, D., Cadranel, J. F., et al. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-6 · Cited by 492
Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., Pigeyre, M., Verkindt, H., Dharancy, S., Louvet, A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.052 · Cited by 483
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309265 · Cited by 480
Harrison, S. A., Fecht, W., Brunt, E. M., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22575 · Cited by 470 · cited 1×
“such as orlistat (70) or liraglutide (61) have reported a histological improvement proportional to the amount of”
BackgroundLuukkonen, P. K., Zhou, Y., Sädevirta, S., Leivonen, M., Arola, J., Orešič, M., Hyötyläinen, T., & Yki-Järvinen, H. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.002 · Cited by 461
Wang, C., Wang, X., Gong, G., Ben, Q., Qiu, W., Chen, Y., Li, G., & Wang, L. (2012) · International Journal of Cancer · doi:10.1002/ijc.26165 · Cited by 449
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity
Chalasani, N., Aljadhey, H., Kesterson, J., Murray, M. D., & Hall, S. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.015 · Cited by 441
Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440 · cited 1×
“Comparable effects have been observed with equally hypocaloric low-carbohydrate versus high-carbohydrate diets (72) and low-fat versus low-carbohydrate diets (73).”
BackgroundWilliamson, R. M., Price, J. F., Glancy, S., Perry, E., Nee, L. D., Hayes, P. C., Frier, B. M., Van Look, L. A. F., Johnston, G. I., Reynolds, R. M., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2229 · Cited by 391
Statin use and non-alcoholic steatohepatitis in at risk individuals
Dongiovanni, P., Petta, S., Mannisto, V., Mancina, R. M., Pipitone, R., Karja, V., Maggioni, M., Kakela, P., Wiklund, O., Mozzi, E., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.006 · Cited by 390 · cited 1×
“Evidence from retrospective (101) and cross-sectional (102) studies has shown that statins are safe in these patients, and that theymayevencontribute todecreased plasma aminotransferase levels and im-”
BackgroundPentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350
Loomba, R., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J., Kono, Y., Bhatt, A., et al. (2015) · Hepatology · doi:10.1002/hep.27647 · Cited by 344
Independent Predictors of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., Goodman, Z., & Younossi, Z. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.007 · Cited by 342
Ioannou, G. N., Boyko, E. J., & Lee, S. P. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00341.x · Cited by 325
Koehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307
Bariatric surgery for non-alcoholic steatohepatitis in obese patients
Chavez-Tapia, N. C., Tellez-Avila, F. I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., & Uribe, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007340.pub2 · Cited by 297
Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285 · cited 1×
“Of note, histological improvement after pioglitazone therapy is closely correlated with the reversal of adipose tissue insulin resistance (84) and an increase in plasma adiponectin levels (85).”
BackgroundSelf-citationCusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz-Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.042 · Cited by 273
Self-citationLin, S. C., Heba, E., Wolfson, T., Ang, B., Gamst, A., Han, A., Erdman, J. W., O’Brien, W. D., Andre, M. P., Sirlin, C. B., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.027 · Cited by 254
Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., Hardies, J., & Cusi, K. (2012) · Diabetes Care · doi:10.2337/dc11-1849 · Cited by 253
Self-citationThe effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Lutchman, G., Modi, A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M., Borg, B., Loomba, R., Liang, T. J., Premkumar, A., et al. (2007) · Hepatology · doi:10.1002/hep.21661 · Cited by 244
Bril, F., Ortiz‐Lopez, C., Lomonaco, R., Orsak, B., Freckleton, M., Chintapalli, K., Hardies, J., Lai, S., Solano, F., Tio, F., et al. (2015) · Liver International · doi:10.1111/liv.12840 · Cited by 237
Self-citationPioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237 · cited 1×
“, one extra case per 3,408 patients treated with extended treatment) (93), although a larger 10-year prospective study failed to find any association (94).”
BackgroundSiddiqui, M. S., Fuchs, M., Idowu, M. O., Luketic, V. A., Boyett, S., Sargeant, C., Stravitz, R. T., Puri, P., Matherly, S., Sterling, R. K., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.10.008 · Cited by 231
Nelson, A., Torres, D. M., Morgan, A. E., Fincke, C., & Harrison, S. A. (2009) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31819c392e · Cited by 230
Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease
Zein, C. O., Unalp, A., Colvin, R., Liu, Y.-C., & McCullough, A. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.040 · Cited by 227
Argo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Doycheva, I., Cui, J., Nguyen, P., Costa, E. A., Hooker, J., Hofflich, H., Bettencourt, R., Brouha, S., Sirlin, C. B., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13405 · Cited by 210
Bazick, J., Donithan, M., Neuschwander-Tetri, B. A., Kleiner, D., Brunt, E. M., Wilson, L., Doo, E., Lavine, J., Tonascia, J., & Loomba, R. (2015) · Diabetes Care · doi:10.2337/dc14-1239 · Cited by 206
Poynard, T., Lebray, P., Ingiliz, P., Varaut, A., Varsat, B., Ngo, Y., Norha, P., Munteanu, M., Drane, F., Messous, D., et al. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-40 · Cited by 200
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD), Sumida, Y., Yoneda, M., Hyogo, H., Yamaguchi, K., Ono, M., Fujii, H., Eguchi, Y., Suzuki, Y., Imai, S., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-010-0305-6 · Cited by 199
McKimmie, R. L., Daniel, K. R., Carr, J. J., Bowden, D. W., Freedman, B. I., Register, T. C., Hsu, F.-C., Lohman, K. K., Weinberg, R. B., & Wagenknecht, L. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02188.x · Cited by 189
Dumas, M., Kinross, J., & Nicholson, J. K. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.001 · Cited by 187
Torres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L., & Vancica, L. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.942 · Cited by 177
Adams, L. A., George, J., Bugianesi, E., Rossi, E., De Boer, W. B., van der Poorten, D., Ching, H. L. I., Bulsara, M., & Jeffrey, G. P. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06774.x · Cited by 172
Bril, F., Lomonaco, R., Orsak, B., Ortiz-Lopez, C., Webb, A., Tio, F., Hecht, J., & Cusi, K. (2014) · Hepatology · doi:10.1002/hep.26988 · Cited by 171
Self-citationBril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo Sanchez, P., Biernacki, D., Maximos, M., Lomonaco, R., Orsak, B., Suman, A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3111 · Cited by 168
Self-citationCuthbertson, D. J., Weickert, M. O., Lythgoe, D., Sprung, V. S., Dobson, R., Shoajee-Moradie, F., Umpleby, M., Pfeiffer, A. F. H., Thomas, E. L., Bell, J. D., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0112 · Cited by 164
Targher, G., Bertolini, L., Chonchol, M., Rodella, S., Zoppini, G., Lippi, G., Zenari, L., & Bonora, E. (2010) · Diabetologia · doi:10.1007/s00125-010-1720-1 · Cited by 158
The Future of Thiazolidinedione Therapy in the Management of Type 2 Diabetes Mellitus
Yau, H., Rivera, K., Lomonaco, R., & Cusi, K. J. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0378-8 · Cited by 153
Self-citationMetabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
Lomonaco, R., Bril, F., Portillo-Sanchez, P., Ortiz-Lopez, C., Orsak, B., Biernacki, D., Lo, M., Suman, A., Weber, M. H., & Cusi, K. (2016) · Diabetes Care · doi:10.2337/dc15-1876 · Cited by 146
Self-citationTakeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K., Misu, H., Ota, T., Nakamura, M., Yamada, K., et al. (2014) · Diabetologia · doi:10.1007/s00125-013-3149-9 · Cited by 145
Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease
Koliaki, C. C., & Roden, M. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.06.002 · Cited by 144
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141 · cited 1×
“with insulin (96) or an improvement of plasma aminotransferase levels after sodium–glucose cotransporter 2 inhibitor”
BackgroundLifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
Hannah, W. N., & Harrison, S. A. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4153-y · Cited by 139
Cusi, K. (2016) · Diabetologia · doi:10.1007/s00125-016-3952-1 · Cited by 137
Self-citationEffect of canagliflozin on liver function tests in patients with type 2 diabetes
Leiter, L. A., Forst, T. M., Polidori, D., Balis, D. A., Xie, J., & Sha, S. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.10.003 · Cited by 133
Bril, F., Maximos, M., Portillo-Sánchez, P., Biernacki, D., Lomonaco, R., SUBBARAYAN, S. K., Correa, M., Lo, M. C., Suman, A., & Cusi, K. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.040 · Cited by 123
Self-citationPioglitazone in the treatment of NASH: the role of adiponectin
Gastaldelli, A., Harrison, S., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 113
Self-citationRenin‐angiotensin system and fibrosis in non‐alcoholic fatty liver disease
Goh, G. B., Pagadala, M. R., Dasarathy, J., Unalp‐Arida, A., Sargent, R., Hawkins, C., Sourianarayanane, A., Khiyami, A., Yerian, L., Pai, R., et al. (2015) · Liver International · doi:10.1111/liv.12611 · Cited by 113
Diagnosis of non-alcoholic fatty liver disease (NAFLD)
Yki-Järvinen, H. (2016) · Diabetologia · doi:10.1007/s00125-016-3944-1 · Cited by 103
Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients
Hamaguchi, E., Takamura, T., Sakurai, M., Mizukoshi, E., Zen, Y., Takeshita, Y., Kurita, S., Arai, K., Yamashita, T., Sasaki, M., et al. (2010) · Diabetes Care · doi:10.2337/dc09-0148 · Cited by 102
The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
Forlani, G., Giorda, C., Manti, R., Mazzella, N., De Cosmo, S., Rossi, M. C., Nicolucci, A., Di Bartolo, P., Ceriello, A., Guida, P., et al. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2931985 · Cited by 100
Statins Are Underutilized in Patients with Nonalcoholic Fatty Liver Disease and Dyslipidemia
Blais, P., Lin, M. F., Kramer, J. R., El‐Serag, H. B., & Kanwal, F. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4000-6 · Cited by 97
Practice patterns in NAFLD and NASH: real life differs from published guidelines
Rinella, M. E., Lominadze, Z., Loomba, R., Charlton, M., Neuschwander-Tetri, B. A., Caldwell, S. H., Kowdley, K., & Harrison, S. A. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15611581 · Cited by 95
Hepburn, M. J., Vos, J. A., Fillman, E. P., & Lawitz, E. J. (2005) · BMC Gastroenterology · doi:10.1186/1471-230x-5-14 · Cited by 88
Carvalhana, S. C., Leitão, J., Alves, A. C., Bourbon, M., & Cortez‐Pinto, H. (2013) · Liver International · doi:10.1111/liv.12305 · Cited by 88
Kim, S. H., Lee, J. M., Kim, J. H., Kim, K. G., Han, J. K., Lee, K. H., Park, S. H., Yi, N.-J., Suh, K.-S., An, S. K., et al. (2005) · Radiology · doi:10.1148/radiol.2343040142 · Cited by 81
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Castera, L. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562948 · Cited by 81
NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes
Bugianesi, E., Vanni, E., & Marchesini, G. (2007) · Current Diabetes Reports · doi:10.1007/s11892-007-0029-z · Cited by 78
Szendroedi, J., Anderwald, C., Krssak, M., Bayerle-Eder, M., Esterbauer, H., Pfeiler, G., Brehm, A., Nowotny, P., Hofer, A., Waldhäusl, W., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1123 · Cited by 53
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Tota-Maharaj, R., Blaha, M. J., Zeb, I., Katz, R., Blankstein, R., Blumenthal, R. S., Budoff, M. J., & Nasir, K. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.12.015 · Cited by 48
Long, M. T., Pedley, A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157517 · Cited by 40
The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease
Bril, F., Lomonaco, R., & Cusi, K. (2012) · Clinical Lipidology · doi:10.2217/clp.12.47 · Cited by 32
Self-citationPrognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
Perazzo, H., Munteanu, M., Ngo, Y., Lebray, P., Seurat, N., Rutka, F., Couteau, M., Jacqueminet, S., Giral, P., Monneret, D., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12946 · Cited by 31
Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Bril, F., Ntim, K., Lomonaco, R., & Cusi, K. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch20 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Sanyal, 2016, Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: results from the Year 1 primary analysis of the Phase 2b CENTAUR study (Abstract), Hepatology, 64, 1118A
Cited by
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Self-citationStefan, N., Häring, H.-U., & Cusi, K. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 837
Self-citation
Metadata
- Authors
- Bril, F., & Cusi, K.
- Affiliations
- University of Florida Health (US)
- Corresponding author
- Cusi, Kenneth
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-02-13
- Volume
- 40
- Issue
- 3
- Pages
- 419-430
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2589426226
- Cited by
- 341
- References
- 123
- Citations by year
- 2026: 14 · 2025: 21 · 2024: 28 · 2023: 38 · 2022: 41 · 2021: 43 · 2020: 61 · 2019: 41 · 2018: 36 · 2017: 17
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, type 2 diabetes, nonalcoholic steatohepatitis, metabolic syndrome, obesity, liver cirrhosis, hepatocellular carcinoma, NASH diagnosis, NASH treatment, disease natural history
- MeSH terms
- Diabetes Mellitus, Type 2, Carcinoma, Hepatocellular, Humans, Hyperglycemia, Life Style, Liver Neoplasms, Obesity, Risk Factors, Prevalence, Randomized Controlled Trials as Topic, Metabolic Syndrome, Dyslipidemias, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.